HERON THERAPEUTICS
Heron Therapeutics Inc, formerly A.P. Pharma, Inc. is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery platform. The Company’s lead product candidate, APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company’s Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.
HERON THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
1987-01-01
Address:
Redwood City, California, United States
Country:
United States
Website Url:
http://www.herontx.com
Total Employee:
101+
Status:
Active
Contact:
800-962-4284
Email Addresses:
[email protected]
Total Funding:
450.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt WordPress Content Delivery Network Wordpress Plugins Nginx
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Current Employees Featured
Founder
Stock Details
Investors List
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Heron Therapeutics
Broadfin Capital
Broadfin Capital investment in Post-IPO Equity - Heron Therapeutics
Great Point Partners
Great Point Partners investment in Post-IPO Equity - Heron Therapeutics
Tang Capital Management
Tang Capital Management investment in Post-IPO Equity - Heron Therapeutics
Newest Events participated
Official Site Inspections
http://www.herontx.com Semrush global rank: 1.66 M Semrush visits lastest month: 14.88 K
- Host name: 52.57.237.35.bc.googleusercontent.com
- IP address: 35.237.57.52
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Heron Therapeutics"
Developing Best-in-Class Medicine. Improving lives.
Heron Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number 800-962-4284 Heron Therapeutics is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery platform.See details»
Contact Us - Heron Therapeutics
Oct 29, 2024 Email: [email protected]. General Information. 844-HERON11 (844-437-6611) [email protected] Or use the form below on this page. Corporate Contact / Business …See details»
Heron Therapeutics - Overview, News & Similar companies
Apr 16, 2024 www.herontx.com. Revenue $122.8 Million. Stock Symbol HRTX. Industry Pharmaceuticals Healthcare . Recent News & Media. Heron Therapeutics, Inc. (HRTX) Q1 …See details»
Heron Therapeutics: Contact Details, Revenue, Funding, Employees …
Email: ***@herontx.com; Buy the List to Unlock Contacts. Similar companies. Anthropic Personalis DNAnexus LOLIWARE 23andMe Molecular Devices Frequently Asked Questions …See details»
Heron Therapeutics, Inc. (HRTX) - Yahoo Finance
See the company profile for Heron Therapeutics, Inc. (HRTX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and ...See details»
Heron Therapeutics Announces New CEO and Board Chairman
Apr 3, 2023 For more information, visit www.herontx.com. Forward-Looking Statements . This news release contains "forward-looking statements" as defined by the Private Securities …See details»
Working At Heron Therapeutics: Company Overview and Culture
Mar 14, 2024 www.herontx.com. Organization Type. Public. CEO. Barry Quart Pharm.d. Heron Therapeutics Inc, formerly A.P. Pharma, Inc. is a specialty pharmaceutical company …See details»
Heron Therapeutics, Inc. (HRTX) Company Profile & Overview
Ticker Symbol: HRTX: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: CIK Code: 0000818033: CUSIP Number: 427746102: ISIN Number: …See details»
Management - Heron Therapeutics
Prior to joining Heron, Dr. Forbes served as the Chief Development Officer at Trevi Therapeutics, Inc. from 2021 to 2022. From 2016 to 2020, Dr. Forbes served as the President and CEO of …See details»
Heron Therapeutics Announces Commercial Leadership Changes
SAN DIEGO, April 20, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron"), a commercial-stage biotechnology company focused on improving the lives of patients by …See details»
Corporate Presentations - Heron Therapeutics
The Investor Relations website contains information about Heron Therapeutics's business for stockholders, potential investors, and financial analysts.See details»
News Release Details - Heron Therapeutics
May 11, 2023 The conference call can be accessed by dialing (646) 307-1963 for domestic callers and (800) 715-9871 for international callers. Please provide the operator with the …See details»
Our Focus - Acute Care and Oncology Care | Heron Therapeutics
Oct 29, 2024 Dec 3 2024 - U.S. District Court Upholds Validity of CINVANTI® Patents . Nov 12 2024 - Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows....See details»
Compliance - Heron Therapeutics
Oct 29, 2024 Our Compliance Program is available to the public on our corporate website, and interested parties may also obtain a copy by emailing [email protected]. Heron …See details»
Heron Therapeutics Announces First Quarter 2024 Financial …
May 7, 2024 The conference call can be accessed by dialing (646) 307-1963 for domestic callers and (800) 715-9871 for international callers. Please provide the operator with the …See details»
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 ...
SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a …See details»
Heron Therapeutics Highlights Progress in Acute Care and …
Jan 9, 2023 - Preliminary Annual Net Product Sales Across the Company Grew 24% to $106.7 Million in 2022, Compared to Annual Net Product Sales in 2021 - - Preliminary Fourth-Quarter …See details»
Acute Care and Oncology Care - Product Pipeline - Heron …
Dec 3 2024 - U.S. District Court Upholds Validity of CINVANTI® Patents . Nov 12 2024 - Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows.... Nov 4 2024 - …See details»